Potential use of n-3 PUFAs to prevent oxidative stress-derived ototoxicity caused by platinum-based chemotherapy
Author
dc.contributor.author
Cortés Fuentes, Ignacio A.
Author
dc.contributor.author
Burotto, Mauricio
Author
dc.contributor.author
Retamal, Mauricio A.
Author
dc.contributor.author
Frelinghuysen, Michael
Author
dc.contributor.author
Caglevic, Christian
Author
dc.contributor.author
Gormaz, Juan G.
Admission date
dc.date.accessioned
2021-07-01T23:38:11Z
Available date
dc.date.available
2021-07-01T23:38:11Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Free Radical Biology and Medicine 160 (2020) 263–276
es_ES
Identifier
dc.identifier.other
10.1016/j.freeradbiomed.2020.07.035
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/180364
Abstract
dc.description.abstract
Platinum-based compounds are widely used for the treatment of different malignancies due to their high effectiveness.
Unfortunately, platinum-based treatment may lead to ototoxicity, an often-irreversible side effect
without a known effective treatment and prevention plan. Platinum-based compound-related ototoxicity results
mainly from the production of toxic levels of reactive oxygen species (ROS) rather than DNA-adduct formation,
which has led to test strategies based on direct ROS scavengers to ameliorate hearing loss. However, favorable
clinical results have been associated with several complications, including potential interactions with chemotherapy
efficacy. To understand the contribution of the different cytotoxic mechanisms of platinum analogues
on malignant cells and auditory cells, the particular susceptibility and response of both kinds of cells to molecules
that potentially interfere with these mechanisms, is fundamental to develop innovative strategies to prevent
ototoxicity without affecting antineoplastic effects. The n-3 long-chain polyunsaturated fatty acids (n-3
PUFAs) have been tried in different clinical settings, including with cancer patients. Nevertheless, their use to
decrease cisplatin-induced ototoxicity has not been explored to date. In this hypothesis paper, we address the
mechanisms of platinum compounds-derived ototoxicity, focusing on the differences between the effects of these
compounds in neoplastic versus auditory cells. We discuss the basis for a strategic use of n-3 PUFAs to potentially
protect auditory cells from platinum-derived injury without affecting neoplastic cells and chemotherapy efficacy.
es_ES
Patrocinador
dc.description.sponsorship
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT FONDECYT
11150999